Listen on the go
CORRECT!
Next question
touchHAEMATOLOGY touchHAEMATOLOGY

Start Learning

Touch Loading image
CONFERENCE HUB
Start Learning
Is there an alternative to intensive chemotherapy for patients with acute myeloid leukemia? Key insights from ASH 2024
JOURNALS
Start Learning
Novel CD7-targeted CAR T-cell therapy elicits strong responses in relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma
CONFERENCE HUB
Start Learning
Empowering young haematologists: Insights from the EBMT Trainee Committee co-chairs
touchFEATURE
Start Learning
Isatuximab demonstrated consistent PFS benefits across diverse patient profiles in RRMM in 2 pivotal trials
Sponsored content
CONFERENCE HUB
Start Learning
BVd compared to DVd in RRMM: The DREAMM-7 trial
blood anaemia
JOURNALS
Start Learning
New hope for sickle cell treatment
touchFOCUS
Start Learning
Looking to the future in the treatment of steroid-refractory chronic GvHD
CE/CME ACCREDITED
touchPANEL DISCUSSION
Start Learning
Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management
CE/CME ACCREDITED
touchMDT
Start Learning
Recognizing and managing HLH in the critical care setting: Best practice for the multidisciplinary team
CE/CME ACCREDITED
touchPANEL DISCUSSION
Start Learning
Maximizing the possibilities in the evolving treatment paradigm for R/R follicular lymphoma: From optimal sequencing to shared decision-making
CE/CME ACCREDITED

to view Favourites, Keep Notes and Track CME Credits

Favourites
Promising data in advancing CAR T-cell therapy outcomes
View
Is there an alternative to intensive chemotherapy for patients with acute myeloid leukemia? Key insights from ASH 2024
View
Cevostamab in triple-class refractory RRMM: The CAMMA 2 Study
View
Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management
View
A legacy in haematology: Prof. Robin Foà’s path from paediatrics to global impact
View
New hope for sickle cell treatment
View
New study offers hope for motherhood after allogeneic stem cell transplantation
View
ISTH unveils new guidelines for haemophilia treatment
View
EHA 2024: Highlights of the late-breaking abstracts
View
#ASH24: Discover the 2024 late-breaking abstracts
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup